In this report, we reanalysed and integrated twelve public proteomic datasets from CRC samples (containing not only solid tumors but also liquid biopsy samples), to confirm the prognostic potential of a gene expression-based signature (SEC6) at the proteomic level [30], but also for the discovery of new candidate biomarkers capable of predicting patient outcome (CD14, MRC2, PPIA, PRDX1, TXNDC5). Here, EXOC3 is linked to colorectal carcinoma.